UroGen Pharma Ltd.

• UroGen Pharma Ltd. Estimates – NASDAQ:URGN
  TradingView · 23 Oct 2026
• Is FDA Filing Acceptance Altering The Investment Case For UroGen Pharma (URGN)?
  Simply Wall Street · 22 Oct 2026
• UroGen Pharma (URGN) Wins FDA Filing Acceptance, Is The Stock Still Cheap?
  Simply Wall Street · 20 Oct 2026
• H.C. Wainwright reiterates UroGen Pharma stock rating on FDA filing acceptance
  Investing.com · 20 Oct 2026
• FDA accepts UroGen's NDA for UGN-103 in recurrent low-grade intermediate-risk bladder cancer
  Dealroom · 20 Oct 2026
• UroGen Pharma (URGN) FDA Accepts Marketing Application for UGN-1
  GuruFocus · 19 Oct 2026
• FDA accepts UroGen’s drug application for bladder cancer
  Investing.com India · 19 Oct 2026
• UroGen Announces FDA Acceptance of the New Drug Application
  GlobeNewswire · 19 Oct 2026
• UroGen Pharma: An Emerging GARP Stock
  Seeking Alpha · 13 Oct 2026
• UroGen Pharma stock dips 30% after 208% rally o...
  Pluang · 13 Oct 2026
• Form 144 UroGen Pharma Ltd. For: 9 October By Investing.com
  Investing.com Canada · 09 Oct 2026
• UroGen Pharma CFO Chris Degnan sells $80,791 in shares
  Investing.com · 09 Oct 2026

Headlines from the last 30 days, linking to the original publishers. See all market news →